Similarly, a recent study identified a unique protumorigenic CAF subset that expressed CD10 and GPR77 and is involved in cancer stemness and chemoresistance.[8] Together, these studies suggest that the characterization of different CAF subclones based on specific molecular characteristics can not only deepen our insight into the heterogeneity of CAFs but also guide the development of CAF‐targeting precision therapies and mitigate therapeutic resistance. The gene discussed is MME; the disease is cancer.